Charu Aggarwal, MD, MPH

Healio spoke with Charu Aggarwal, MD, MPH, about findings from her poster presentation on the impact on duration of immunotherapy on OS in metastatic non-small cell lung cancer presented at this year’s ASCO Annual Meeting.

Healio spoke with Charu Aggarwal, MD, MPH, about data from the Keynote-789 trial presented at this year’s ASCO Annual Meeting.

Healio spoke with Charu Aggarwal, MD, MPH, about results from the Keynote-671 trial presented at this year’s ASCO Annual Meeting.

Charu Aggarwal, MD, MPH, shared with Healio non-small cell lung cancer studies she is most looking forward to seeing the results of at the ASCO Annual Meeting, taking place June 3-7 in Chicago.

The addition of toripalimab to first-line chemotherapy prolonged PFS and OS among patients with advanced non-small cell lung cancer without EGFR/ALK mutations, according to study results.

In this video, Charu Aggarwal, MD, MPH, discusses presentations in both non-small cell and small cell lung cancer from Chemotherapy Foundation Symposium.

Charu Aggarwal, MD, MPH, spoke with Healio about a presentation she gave at this year’s Chemotherapy Foundation Symposium.

Charu Aggarwal, MD, MPH, said her interest in joining Healio’s Women in Oncology Peer Perspective Board stemmed from the need to provide women in medicine with opportunities for peer mentorship, collaboration and sponsorship.

The addition of first-line ipilimumab to pembrolizumab did not improve outcomes for patients with metastatic non-small cell lung cancer who had PD-L1 tumor proportion scores of 50% or greater and no targetable EGFR or ALK aberrations.

In this video, Charu Aggarwal, MD, MPH, Leslye M. Heisler assistant professor for lung cancer excellence at the University of Pennsylvania Abramson Cancer Center, discusses the role of liquid biopsies for the management of non-small cell lung cancer.